Zachary Sethna
Overview
Explore the profile of Zachary Sethna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al.
Nature
. 2025 Feb;
PMID: 39972124
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may...
2.
Guasp P, Reiche C, Sethna Z, Balachandran V
Cancer Cell
. 2024 Jun;
42(7):1163-1184.
PMID: 38848720
Vaccines are the most impactful medicines to improve health. Though potent against pathogens, vaccines for cancer remain an unfulfilled promise. However, recent advances in RNA technology coupled with scientific and...
3.
Ceglia N, Sethna Z, Freeman S, Uhlitz F, Bojilova V, Rusk N, et al.
Nat Commun
. 2023 Jul;
14(1):4400.
PMID: 37474509
Deciphering individual cell phenotypes from cell-specific transcriptional processes requires high dimensional single cell RNA sequencing. However, current dimensionality reduction methods aggregate sparse gene information across cells, without directly measuring the...
4.
Rojas L, Sethna Z, Soares K, Olcese C, Pang N, Patterson E, et al.
Nature
. 2023 May;
618(7963):144-150.
PMID: 37165196
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines . Here in a phase I trial of adjuvant...
5.
Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade K, Bajorin D, et al.
Nature
. 2022 May;
606(7914):E5.
PMID: 35641605
No abstract available.
6.
Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade K, Bajorin D, et al.
Nature
. 2022 May;
606(7912):172-179.
PMID: 35545680
Missense driver mutations in cancer are concentrated in a few hotspots. Various mechanisms have been proposed to explain this skew, including biased mutational processes, phenotypic differences and immunoediting of neoantigens;...
7.
Sethna Z, Isacchini G, Dupic T, Mora T, Walczak A, Elhanati Y
PLoS Comput Biol
. 2020 Dec;
16(12):e1008394.
PMID: 33296360
The diversity of T-cell receptor (TCR) repertoires is achieved by a combination of two intrinsically stochastic steps: random receptor generation by VDJ recombination, and selection based on the recognition of...
8.
Isacchini G, Sethna Z, Elhanati Y, Nourmohammad A, Walczak A, Mora T
Phys Rev E
. 2020 Jul;
101(6-1):062414.
PMID: 32688532
T-cell receptors (TCR) are key proteins of the adaptive immune system, generated randomly in each individual, whose diversity underlies our ability to recognize infections and malignancies. Modeling the distribution of...
9.
Moral J, Leung J, Rojas L, Ruan J, Zhao J, Sethna Z, et al.
Nature
. 2020 Feb;
579(7797):130-135.
PMID: 32076273
Group 2 innate lymphoid cells (ILC2s) regulate inflammation and immunity in mammalian tissues. Although ILC2s are found in cancers of these tissues, their roles in cancer immunity and immunotherapy are...
10.
Sethna Z, Elhanati Y, Callan C, Walczak A, Mora T
Bioinformatics
. 2019 Jan;
35(17):2974-2981.
PMID: 30657870
Motivation: High-throughput sequencing of large immune repertoires has enabled the development of methods to predict the probability of generation by V(D)J recombination of T- and B-cell receptors of any specific...